TuHURA Biosciences (NASDAQ:HURA) Trading 1.7% Higher – Still a Buy?

TuHURA Biosciences (NASDAQ:HURA)’s stock price shot up 1.7% on Thursday . The stock traded as high as $3.72 and last traded at $3.62. 114,112 shares traded hands during trading, a decline of 59% from the average session volume of 276,926 shares. The stock had previously closed at $3.56.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the company. RODMAN&RENSHAW raised TuHURA Biosciences to a “strong-buy” rating in a report on Thursday, December 19th. HC Wainwright assumed coverage on shares of TuHURA Biosciences in a research report on Monday, March 3rd. They issued a “buy” rating and a $13.00 price target for the company. Finally, Rodman & Renshaw started coverage on TuHURA Biosciences in a research report on Thursday, December 19th. They issued a “buy” rating and a $11.00 target price on the stock.

TuHURA Biosciences Stock Down 2.5 %

The business’s fifty day moving average is $3.55.

Hedge Funds Weigh In On TuHURA Biosciences

Institutional investors and hedge funds have recently bought and sold shares of the stock. Apollon Wealth Management LLC bought a new stake in TuHURA Biosciences in the 4th quarter valued at $253,000. Suncoast Equity Management bought a new position in TuHURA Biosciences during the fourth quarter valued at about $421,000. Accent Capital Management LLC acquired a new position in TuHURA Biosciences in the 4th quarter valued at approximately $29,000. Millennium Management LLC bought a new stake in shares of TuHURA Biosciences in the 4th quarter worth approximately $138,000. Finally, Squarepoint Ops LLC acquired a new stake in shares of TuHURA Biosciences during the 4th quarter worth approximately $223,000. Institutional investors own 0.62% of the company’s stock.

About TuHURA Biosciences

TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.